Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studies

CNS Drugs(2025)10.1007/s40263-025-01194-4Source: DataRank Database

Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studies is a research paper published in CNS Drugs (2025). On theSindex it has a DataRank of 0.165. It has been cited 2 times.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.60)OA: hybridTopics (38)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (7)

Yang Li ORCID,Yishen Yang,Jianmin Zhuo,Miaomiao Jia,Chong Ye

Live enrichment

PubMed:40517352 PMC:PMC12263469 OpenAlex:https://openalex.org/W4411312707

Xian Janssen Pharmaceuticals Co., Ltd.

FWCI

1.60

Citation Percentile

0.8%

Citation Trend

2025

hybridLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40263-025-01194-4.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40263-025-01194-4.pdf

publisherhttps://link.springer.com/article/10.1007/s40263-025-01194-4/fulltext.html

journalhttps://doi.org/10.1007/s40263-025-01194-4

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40517352

Fields of Study

Schizophrenia research and treatmentTryptophan and brain disordersMental Health and Psychiatry

MeSH Terms

Paliperidone PalmitateEast Asian PeopleAdultChinaDelayed-Action PreparationsDrug Administration ScheduleFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesSchizophreniaAntipsychotic AgentsMulticenter Studies as TopicRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase IV as TopicAsian PeopleYoung Adult

Keywords

Paliperidone PalmitatePost-hoc analysisMedicinePaliperidoneSchizophrenia (object-oriented programming)Positive and Negative Syndrome ScaleInternal medicineTolerabilityAdverse effectClinical endpointClinical Global ImpressionAntipsychoticClinical trialPsychiatryPlaceboPsychosis

Sustainable Development Goals

SDG 0: Zero hunger

Efficacy and Safety of Once-Monthly Paliperidone Palmitate Long-Acting Injections in Chinese Patients with Early-, Mid-, and Late-Phase Schizophrenia: A Post-Hoc Analysis of Three Phase 4 Studies

FAIR Checklist

DataRank Breakdown

Authors (7)

Funding (1 grants)

Impact

Open Access

Topics